AveXis — Q2 2016 Earnings Presentation
16 slides from AveXis's earnings presentation, Aug 11, 2016
Slide 1: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains forward-looking statements, including: statements about: the timing, progress and results of preclinical studies and clinical trials for AVXS-101, including statements regarding the timing of initiation and completion of studies or trials and r
Slide 2: Natural History of SMA Type 1
Natural History of SMA Type 1 “floppy baby” syndrome muscle weakness (legs more than arms) poor head control belly breathing bulbar muscle weakness (weak cry, difficulty swallowing, aspiration) will never sit unsupported loss of motor function: NeuroNEXT -- CHOP INTEND decrease of 10.5 points/yr. PN
Slide 3: AVXS-101 Targets the Primary SMN Gene
AVXS-101 Targets the Primary SMN Gene 4 NORMAL INDIVIDUAL SMA-AFFLICTED INDIVIDUAL SMA-AFFLICTED INDIVIDUAL TREATED WITH AVXS-101 SMN Genes SMN Protein SMN1 Primary SMN2 Back up SMN Genes SMN Protein SMN1 SMN2 Back up SMN Genes SMN Protein SMN1 SMN2 Back up AVXS-101 Primary Functional SMN Protein No
Slide 4: SMA Type 1 is a Motor Neuron Disease with both Central and Systemic Features
SMA Type 1 is a Motor Neuron Disease with both Central and Systemic Features 5 Addresses underlying cause of SMA – defective/loss of primary SMN gene Targets motor neurons Provides rapid onset of effect and continuous and sustained SMN expression Crosses blood brain barrier allowing IV dosing route
Slide 5: Our Solution: AVXS-101 An Innovative Treatment Approach for SMA
Our Solution: AVXS-101 An Innovative Treatment Approach for SMA 6 scAAV ITR Continuous Promoter Human SMN Transgene scAAV ITR KEY COMPONENTS PURPOSE Recombinant AAV9 Capsid Shell Ability to deliver across the blood brain barrier (BBB) and into the spinal cord - Avoids the need for intrathecal delive
Slide 6: Phase 1 Trial Design
Phase 1 Trial Design 7 TRIAL OVERVIEW Route of Administration One-time intravenous infusion through peripheral limb vein Prednisolone 1 mg/kg 1 day Pre-GT Trial Design Open-label, dose-escalation Principal Investigator Jerry R. Mendell, M.D. TRIAL OVERVIEW Study Site OBJECTIVES Primary Safety and To
Slide 7: Survival Data – Ongoing Phase 1 Trial
Survival Data – Ongoing Phase 1 Trial, July 1, 2016 * A month is defined as 30 days Cohort 1 6.7E13 vg/kg Cohort 2 2.0E14 vg/kg PNCR (Finkel) 2014 Natural History Study: 75% event-free 50% event-free 25% event-free 8% event-free 8 Day of Gene Transfer Last Trial Visit – Age Fixed SURVIVAL DATA 6/6 r
Slide 8: CHOP INTEND vs. Age: Cohort 1
CHOP INTEND vs. Age: Cohort 1, July 1, 2016 Dashed line denotes missing data for reasons noted below: E.01 – follow-up on Month 17 cancelled due to SAE hospitalization; full CHOP INTEND not conducted on Months 19, 20 and 21 due to broken right arm; full CHOP INTEND not conducted on Months 26, 27, 29
Slide 9: CHOP INTEND vs. Age: Cohort 2
CHOP INTEND vs. Age: Cohort 2, July 1, 2016 10 Dashed line denotes missing data for reasons noted below: E.04 – full CHOP INTEND not conducted on Months 14 and 15 due to body cast for scoliosis; CHOP INTEND not conducted on Month 19 due to scoliosis surgery recovery; CHOP INTEND not conducted on Mon
Slide 10: Change in CHOP INTEND Scores
Change in CHOP INTEND Scores – July 1, 2016 NN101 = NeuroNEXT Natural History Study CHOP INTEND decrease of 10.5 points/yr. +23.3** +9.0 -10.5 11 ** Calculation includes 2 patients who achieved max score COHORT 1 (n=3) Baseline Age (months): 5.9 [median], 6.3 [mean] Current Age* (months): 28.8 [medi
Slide 11: Safety Data – Ongoing Phase 1 Trial
Safety Data – Ongoing Phase 1 Trial – July 1, 2016 SAFETY AND TOLERABILITY OBSERVATIONS No new treatment-related SAEs or AEs observed As previously reported, a total of 5 treatment-related AEs in 4 patients have been observed to date. Treatment-related SAEs and AEs were clinically asymptomatic eleva
Slide 12: Summary: Ongoing Phase 1 Data
Summary: Ongoing Phase 1 Data – July 1, 2016 13 AVXS-101 appears to have a favorable safety profile and appears to be generally well-tolerated A total 107 AEs, 31 SAEs and 76 non-serious AEs observed to date No additional treatment-related AEs have been observed beyond the previously reported five e
Slide 13: Financial Position
Financial Position (dollars in millions) 14 Cash and cash equivalents of $131.4 million as of June 30, 2016 Three months ended 6/30/16 Three months ended 6/30/15 R&D Expense $10.4 $7.7 G&A Expense $5.4 $2.3 Net Loss $15.7 $9.9
Slide 14: Clinical Development Milestones
Clinical Development Milestones 15 2016 2H 2016: Provide update on FDA Type B meeting Q1 2017: 13.6 months of data for all patients in the SMA Type 1 Phase 1 trial 2H 2016: Initiate Phase 1 safety and dosing study in SMA Type 2 via intrathecal (IT) delivery 1H 2017: Initiate SMA Type 1 pivotal trial
Slide 15: Clinical Development Milestones
Clinical Development Milestones 2H 2016: Initiate Phase 1 safety ‘and dosing study in ‘SMA Type 2 via intrathecal (IT) delivery
Slide 16: Question and Answer Session
Question and Answer Session aveRis